Loading stock data…
AXGN
$43.28+0.08 (+0.19%)
Market ClosedLast close May 1
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Axogen, Inc. in the Healthcare sector is trading at $43.28. The stock is currently near its 52-week high of $45.83, remaining 67.6% above its 200-day moving average. Technical signals show overbought RSI of 82 and bullish MACD crossover, explaining why AXGN maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 82) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$43.28
Potential Upside
5%
Whystock Fair Value$45.44
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intende...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.94B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.98
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-22.37%
Volume
Today's trading volume
759,225
Recent News
Axogen, Inc. (NASDAQ:AXGN) Analysts Are Pretty Bullish On The Stock After Recent Results
Shareholders of Axogen, Inc. ( NASDAQ:AXGN ) will be pleased this week, given that the stock price is up 12% to...
Axogen Inc (AXGN) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid Rising Expenses
Axogen Inc (AXGN) reports a robust 26.6% revenue increase in Q1 2026, despite facing higher operating costs and a significant net loss.
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Health care stocks edged up late Tuesday afternoon, with the NYSE Health Care Index fractionally hig
Axogen (AXGN) Q3 2025 Earnings Transcript
Lindsey will then provide details on financial performance, guidance and overall outlook for the year. Today's call and presentation is being broadcast live via webcast, which is available on the Investors section of AxoGen's website. Before we get started, I'd like to remind you that during the conference call, the company will make projections and forward-looking statements.
Axogen (AXGN) Q1 2025 Earnings Transcript
Joining me on today's call is Michael Dale, Axogen's Chief Executive Officer and Director; and Nir Naor, Chief Financial Officer; and Jens Kemp, Chief Marketing Officer. Michael will discuss first quarter 2025 financial results and corporate highlights. Today's call is being broadcast live via webcast, which is available on the Investors section of Axogen's website.